Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KPTI Stock Summary
In the News
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.43 per share a year ago.
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
While targeting the therapeutic side of the healthcare sector can be quite lucrative, nothing matches the excitement of biotech penny stocks. Of course, the excitement goes toward both extremes of the emotional spectrum.
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
Karyopharm Therapeutics (KPTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President and CEO Reshma Rangwala - Chief Medical Officer Sohanya Cheng - Chief Commercial Officer Michael Mason - CFO Conference Call Participants Maury Raycroft - Jefferies Colleen Kusy - Baird Operator Good morning. My name is Guru and I will be your conference operator today.
Penny Stocks To Buy Now? 3 With Ratings Up To 1,742%
In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts.
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.62 per share a year ago.
Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?
Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The Food and Drug Administration (FDA) has granted fast-track designation to the development of selinexor.
All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to Buy
Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual Meetings
NEWTON, Mass. , May 23, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6 in Chicago, Illinois and the 2023 European Hematology Association (EHA) Hybrid Congress, being held June 8-11 in Frankfurt, Germany.
Karyopharm Therapeutics, Inc. (KPTI) Q1 2023 Earnings Call Transcript
Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Medical Officer Michael Mason - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Kevin Strang - Jefferies Colleen Kusy - Robert W. Baird Nicole Gabreski - Piper Sandler Eric Joseph - JPMorgan Operator Good morning.
KPTI Financial details
KPTI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.66 | 1.5 | 2.79 | 1.92 | 1.28 | |
Net income per share | -3.22 | -2.72 | -1.65 | -2.02 | -1.25 | |
Operating cash flow per share | -3.08 | -2.22 | -1.42 | -1.83 | -0.81 | |
Free cash flow per share | -3.08 | -2.23 | -1.5 | -1.83 | -0.81 | |
Cash per share | 4.23 | 3.46 | 3.04 | 3.4 | 1.68 | |
Book value per share | 0.8 | 0.7 | -1.06 | -0.2 | -1.19 | |
Tangible book value per share | 0.8 | 0.7 | -1.06 | -0.2 | -1.19 | |
Share holders equity per share | 0.8 | 0.7 | -1.06 | -0.2 | -1.19 | |
Interest debt per share | 2.05 | 2.04 | 2.63 | 2.42 | 1.73 | |
Market cap | 1.19B | 1.12B | 483.65M | 278.36M | 98.8M | |
Enterprise value | 1.17B | 1.15B | 462.49M | 316.15M | 222.93M | |
P/E ratio | -5.95 | -5.68 | -3.9 | -1.68 | -0.69 | |
Price to sales ratio | 29.04 | 10.32 | 2.31 | 1.77 | 0.68 | |
POCF ratio | -6.22 | -6.96 | -4.52 | -1.86 | -1.07 | |
PFCF ratio | -6.22 | -6.95 | -4.29 | -1.86 | -1.07 | |
P/B Ratio | 23.86 | 22.06 | -6.07 | -16.71 | -0.73 | |
PTB ratio | 23.86 | 22.06 | -6.07 | -16.71 | -0.73 | |
EV to sales | 28.58 | 10.61 | 2.2 | 2.01 | 1.53 | |
Enterprise value over EBITDA | -6.35 | -6.8 | -4.73 | -2.26 | -1.73 | |
EV to operating cash flow | -6.12 | -7.16 | -4.32 | -2.11 | -2.4 | |
EV to free cash flow | -6.12 | -7.15 | -4.1 | -2.11 | -2.4 | |
Earnings yield | -0.17 | -0.18 | -0.26 | -0.59 | -1.45 | |
Free cash flow yield | -0.16 | -0.14 | -0.23 | -0.54 | -0.94 | |
Debt to equity | 2.24 | 2.37 | -2.15 | -10.39 | -1.28 | |
Debt to assets | 0.38 | 0.38 | 0.56 | 0.48 | 0.72 | |
Net debt to EBITDA | 0.1 | -0.19 | 0.22 | -0.27 | -0.96 | |
Current ratio | 5.9 | 974.88 | 3.5 | 4.96 | 3.37 | |
Interest coverage | -12.1 | -6.33 | -3.77 | -5.69 | -5.44 | |
Income quality | 0.96 | 0.82 | 0.86 | 0.9 | 0.65 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 1.17 | 0.69 | 0.93 | 0.9 | |
Research and developement to revenue | 2.99 | 1.4 | 0.77 | 0.95 | 0.95 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.05 | 0 | 0 | |
Capex to revenue | -0.01 | 0 | -0.03 | 0 | 0 | |
Capex to depreciation | -0.21 | -0.15 | -7.24 | -0.19 | 0 | |
Stock based compensation to revenue | 0.37 | 0.23 | 0.14 | 0.23 | 0.15 | |
Graham number | 7.63 | 6.56 | 6.27 | 3.04 | 5.8 | |
ROIC | -1.07 | -0.94 | -0.95 | -0.86 | -3.18 | |
Return on tangible assets | -0.68 | -0.63 | -0.41 | -0.46 | -0.6 | |
Graham Net | 0.37 | -0.03 | -1.83 | -0.73 | -1.43 | |
Working capital | 227.32M | 289.24M | 184.38M | 260.84M | 164.44M | |
Tangible asset value | 49.77M | 50.55M | -79.67M | -16.66M | -136.21M | |
Net current asset value | 28.48M | 27.04M | -126.88M | -48.08M | -142.72M | |
Invested capital | 2.24 | 2.37 | -2.15 | -10.39 | -1.28 | |
Average receivables | 3.93M | 10.37M | 17.69M | 34.79M | 37.02M | |
Average payables | 2.66M | 2.72M | 3.03M | 2.19M | 2.95M | |
Average inventory | 173K | 1.5M | 3.38M | 4.17M | 3.63M | |
Days sales outstanding | 70.17 | 43.5 | 39.14 | 109.42 | 67.39 | |
Days payables outstanding | 149.37 | 600.46 | 171.99 | 194.16 | 208.31 | |
Days of inventory on hand | 52.47 | 356.77 | 440.53 | 295.75 | 202.98 | |
Receivables turnover | 5.2 | 8.39 | 9.33 | 3.34 | 5.42 | |
Payables turnover | 2.44 | 0.61 | 2.12 | 1.88 | 1.75 | |
Inventory turnover | 6.96 | 1.02 | 0.83 | 1.23 | 1.8 | |
ROE | -4.01 | -3.88 | 1.56 | 9.92 | 1.05 | |
Capex per share | 0 | 0 | -0.08 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.37 | 0.34 | 0.33 | 0.31 | 0.29 | |
Net income per share | -0.43 | -0.3 | -0.29 | -0.3 | -0.36 | |
Operating cash flow per share | -0.3 | -0.17 | -0.23 | -0.26 | -0.16 | |
Free cash flow per share | -0.3 | -0.17 | -0.23 | -0.26 | -0.16 | |
Cash per share | 3.09 | 2.29 | 2.1 | 1.82 | 1.67 | |
Book value per share | -0.19 | -0.4 | -0.63 | -0.88 | -1.19 | |
Tangible book value per share | -0.19 | -0.4 | -0.63 | -0.88 | -1.19 | |
Share holders equity per share | -0.19 | -0.4 | -0.63 | -0.88 | -1.19 | |
Interest debt per share | 1.99 | 1.58 | 1.63 | 1.57 | 1.57 | |
Market cap | 305.78M | 441.44M | 201.41M | 153.3M | 99.28M | |
Enterprise value | 343.56M | 527.69M | 298.59M | 280.34M | 223.41M | |
P/E ratio | -1.99 | -3.23 | -1.54 | -1.11 | -0.59 | |
Price to sales ratio | 9.11 | 11.41 | 5.36 | 4.26 | 2.94 | |
POCF ratio | -11.39 | -23.34 | -7.84 | -5.19 | -5.34 | |
PFCF ratio | -11.42 | -23.34 | -7.84 | -5.19 | -5.34 | |
P/B Ratio | -18.36 | -9.77 | -2.83 | -1.53 | -0.73 | |
PTB ratio | -18.36 | -9.77 | -2.83 | -1.53 | -0.73 | |
EV to sales | 10.23 | 13.64 | 7.95 | 7.79 | 6.62 | |
Enterprise value over EBITDA | -10.56 | -18.64 | -11.21 | -9.86 | -5.92 | |
EV to operating cash flow | -12.8 | -27.91 | -11.62 | -9.49 | -12.02 | |
EV to free cash flow | -12.84 | -27.91 | -11.62 | -9.49 | -12.02 | |
Earnings yield | -0.13 | -0.08 | -0.16 | -0.23 | -0.42 | |
Free cash flow yield | -0.09 | -0.04 | -0.13 | -0.19 | -0.19 | |
Debt to equity | -10.39 | -3.84 | -2.5 | -1.73 | -1.28 | |
Debt to assets | 0.48 | 0.53 | 0.6 | 0.64 | 0.72 | |
Net debt to EBITDA | -1.16 | -3.05 | -3.65 | -4.47 | -3.29 | |
Current ratio | 4.96 | 4.83 | 4.94 | 3.98 | 3.37 | |
Interest coverage | -5.76 | -5.37 | -5.11 | -5.15 | -6.09 | |
Income quality | 0.7 | 0.55 | 0.79 | 0.86 | 0.44 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.03 | 0.93 | 0.92 | 0.86 | 0.91 | |
Research and developement to revenue | 0.92 | 0.84 | 0.84 | 0.99 | 1.16 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0.7 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.18 | 0.14 | 0.16 | 0.14 | 0.15 | |
Graham number | 1.34 | 1.64 | 2.03 | 2.44 | 3.12 | |
ROIC | -0.21 | -0.23 | -0.26 | -0.39 | -0.93 | |
Return on tangible assets | -0.11 | -0.1 | -0.11 | -0.13 | -0.17 | |
Graham Net | -0.66 | -0.73 | -0.94 | -1.15 | -1.42 | |
Working capital | 260.84M | 235.51M | 232.45M | 185.09M | 164.44M | |
Tangible asset value | -16.66M | -45.17M | -71.25M | -100.4M | -136.21M | |
Net current asset value | -48.08M | -73.91M | -77.7M | -123.19M | -142.72M | |
Invested capital | -10.39 | -3.84 | -2.5 | -1.73 | -1.28 | |
Average receivables | 37.27M | 41.14M | 33.74M | 35.1M | 32.44M | |
Average payables | 1.79M | 5.91M | 5.67M | 1.62M | 2.03M | |
Average inventory | 4.24M | 4.03M | 3.75M | 3.39M | 3.07M | |
Days sales outstanding | 126.2 | 81.86 | 77.31 | 94.78 | 71.91 | |
Days payables outstanding | 133.6 | 602.55 | 172.39 | 93.16 | 179.83 | |
Days of inventory on hand | 203.51 | 254.94 | 276.78 | 306.75 | 175.22 | |
Receivables turnover | 0.71 | 1.1 | 1.16 | 0.95 | 1.25 | |
Payables turnover | 0.67 | 0.15 | 0.52 | 0.97 | 0.5 | |
Inventory turnover | 0.44 | 0.35 | 0.33 | 0.29 | 0.51 | |
ROE | 2.31 | 0.76 | 0.46 | 0.34 | 0.31 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
KPTI Frequently Asked Questions
What is Karyopharm Therapeutics Inc. stock symbol ?
Karyopharm Therapeutics Inc. is a US stock , located in Newton of Ma and trading under the symbol KPTI
Is Karyopharm Therapeutics Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $9. The lowest prediction is $5 and the highest is $14
What is KPTI stock prediction ?
What is Karyopharm Therapeutics Inc. stock quote today ?
Karyopharm Therapeutics Inc. stock price is $1.525 today.
Is Karyopharm Therapeutics Inc. stock public?
Yes, Karyopharm Therapeutics Inc. is a publicly traded company.